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Abstract. Erlotinib is an inhibitor of the tyrosine-kinase
domain of the epidermal growth factor receptor-1 (EGFR).
This drug is used to treat some solid cancers, particularly
advanced non-small-cell lung carcinoma. Similar to other
EGFR inhibitors, erlotinib is responsible for a series of skin
adverse reactions, particularly acneiform lesions. We  described
the incidental effect of erlotinib on actinic keratoses which
became markedly inflamed and showed partial regression.
Inflammation appeared to spontaneously decrease while on
erlotinib treatment. This reaction in the skin neoplasm is
perhaps a visible and accessible model for predicting the effect
in the deep-seated neoplasm targeted by the drug.
1. Introduction
Erlotinib (Tarceva®, Roche Pharma) is a small molecule
inhibiting the tyrosine-kinase activity of the EGF receptor
(EGFR). The EGFR family is part of a complex signal-
transduction network that is central to several critical cellular
processes (1). The human EGFR family is disregulated in
many solid tumors, making it an attractive target for anti-
cancer therapy. Erlotinib specifically binds to the cytoplasmic
domain of the EGFR and has been approved in recent years
for chemotherapy-resistant non-small-cell lung carcinoma
(NSCLC) (2-6). This drug is also employed for the treatment
of a few other solid tumors (7).
Treatments with erlotinib, and other EGFR inhibitors as
well, are frequently responsible for cutaneous adverse effects.
These unwanted reactions are quite typical for this drug
family, and distinct from the skin adverse effects related to
other types of anti-cancer chemotherapy (8). The most
frequent skin manifestation following anti-EGFR treatment
consists of an acneiform pustular eruption (9-11). Other
dermatologic reactions include paronychia and some nail
changes, abnormalities in hair growth, xerosis, hyper-
sensitivity reactions, non-specific maculopapular rashes,
stomatitis, mucositis and pruritus (9-11). One case report
described the incidental development of inflammation of
previously undetected actinic keratoses while on sorafenib
therapy (12). We presently report the self-limited inflam-
matory flare-up of actinic keratoses during erlotinib treatment.
To the best of our knowledge, this condition has never been
reported as a complication of erlotinib treatment.
2. Actinic keratoses and squamous cell carcinomas
Chronically sun-exposed skin of the face is susceptible to
develop actinic keratoses which are at risk to evolve into
squamous cell carcinomas (13-15). These lesions are
increasingly recognized in individuals at the age when
internal cancers are also prevalent (16,17).
There are many methods for treating actinic keratoses
(18). Physical procedures for destroying the lesions are
commonly used. Some specific topical drugs are also
employed. Among them, imiquimod and 5-fluorouracil have
proven their efficacy (19). Inflammation is typically present
during their regression phase (20,21), but also conversely
during progression of actinic keratoses to squamous cell
carcinomas (22).
Other conventional chemotherapeutic agents which have
been associated with the inflammation of actinic keratosis
include docetaxel, doxorubicin, capecitabine, pentostatin,
sorafenib and the combination of dactinomycin, vincristine,
dacarbazine and doxorubicin, cytarabine and 6-thioguanine
(8,12,23,24). The mechanism by which these agents lead to
this effect is unknown, although abnormal DNA synthesis
and a form of radiation recall have been postulated (12).
3. Erlotinib and actinic keratoses
The effect of erlotinib on actinic keratoses was first
documented as an incidental finding in a 77-year-old man
treated for a cisplatin-resistant NSCLC. This phototype 2
patient had also been previously treated for several actinic
keratoses and basal cell carcinomas developed on photo-
exposed areas. The actinic keratoses which were not responsive
to topical 5-fluorouracil were destroyed by electrocoagulation.
In addition, a total of 28 basal cell carcinomas were
surgically excised over a period of years and were submitted
for histopathologic confirmation.
Two years ago, the patient was diagnosed with a T2 N1
M0 NSCLC and treated by lobar excision and radiotherapy.
One year later, abdominal metastases developed. They were
first treated with cisplatin chemotherapy without any obvious
clinical response. Recently, a therapy of 150 mg/day erlotinib
(Tarceva) was initiated.
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At day 10 of erlotinib treatment, itchy pustules appeared
on the face, trunk and limbs (Figs. 1 and 2). Crusts formed on
the scalp and a xerotic dermatitis developed mainly on the
arms. These manifestations corresponded to the typical adverse
effects of erlotinib. They were treated with limecycline,
300 mg x 2/day, benzoyl peroxide gel on the face and
mometasone furoate solution on the scalp. Treatment with
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Figure 1. Itchy pustules and patches of serosquamous material on the face at
day 10 of erlotinib treatment.
Figure 2. Histological characteristics of a follicular pustule on the face.
Figure 3. Clinical characteristics of inflammatory changes at the site of the
actinic keratoses on day 10 of erlotinib treatment.
Figure 4. Crust and superficial necrosis of an actinic keratosis.
a
b
Figure 5. (a) Histological characteristics of actinic keratosis. (b) Neoplastic
epithelial dissociation by an intense inflammatory infiltrate with tissue
destruction and neoplastic regression.
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erlotinib was continued. A marked improvement of the
pustular eruption and of the squamous dermatitis of the scalp
was observed after approximately three weeks.
Upon examination 10 days after starting erlotinib treatment,
inflammatory changes were present at the site of the actinic
keratoses on the face (Fig. 3). They led to squame-crust
formation underlined by superficial necrosis of the epithelial
tumors (Fig. 4). After clearing away the necrotic debris,
healing was observed. A biopsy was taken at day 20 of
erlotinib treatment. The microscopic examination showed the
typical epidermal characteristics of actinic keratosis/in situ
squamous cell carcinoma (Fig. 5a). The density of the
lymphoid cell infiltrate was quite extensive. The epidermal
neoplasm was focally infiltrated and dissociated by the
inflammatory cells. At these sites, there were discrete signs of
neoplastic regression and partial destruction (Fig. 5b). Two
months later, the skin lesions were unchanged (Fig. 6) but the
general status of the patient was progressively altered.
Since that initial case of inflammatory actinic keratoses
while on erlotinib treatment, a few other cases were observed
by our staff members. However, these cases are too few to
allow any assessment of the incidence of this condition. 
4. EGFR inhibitors and inflamed actinic keratosis in
perspective
There is a conceptual controversy regarding actinic keratosis
as a precursor of, or as an already in situ squamous cell
carcinoma (16,25-27). It is also uncertain whether to interpret
inflammation of actinic keratosis as a sign of neoplastic
progression or regression (22). In any case the severity of the
histological grading of the neoplasm is important to consider.
Indeed, any inflammatory change in incipient or superficial
actinic keratosis is of little importance in the short term
because the risk of dermal invasion and distant metastasis is
minimal or absent. By contrast, the thicker lesions ready to
evolve into a full-blown squamous cell carcinoma are more
problematic. Tragically, the few months of survival time
expected of the patients undergoing anti-EGFR therapy for a
metastatic NSCLC will likely not be affected by any
progression of actinic keratoses.
More importantly, the effect of erlotinib on actinic
keratoses and in situ squamous cell carcinoma might be
regarded as a model in the understanding of the drug's effect
on internal carcinomas including NSCLC. The reactions at
these skin sites might possibly be better correlated with the
efficacy of the drug on the target neoplasm than with any
other cutaneous sign (28,29). In this condition, the role of the
inflammatory cell infiltrate is probably similar to that of a
bystander. Indeed, the drug is expected to exert a primary
effect on the neoplastic cells themselves. The inflammatory
cell reaction is limited to a secondary reactive process to the
neoplastic damages. This condition would therefore be
different from the usual immune response mounted against
neoplasms and occasionally inducing a partial or total
regression.
5. Conclusion
We reported an undescribed adverse effect of erlotinib at the
site of actinic keratoses. The lesions became inflamed and
showed partial regression. We did not encounter a complete
clearing of these tumors.
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months of erlotinib treatment.
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